Aurobindo Pharma Limited and Covaxx, a US-based company, have entered into an Exclusive License Agreement to develop, commercialize and manufacture UB-612, the first Multitope Peptide-based vaccine to fight COVID-19, for India and the UN Children's Fund (Unicef) agency
